Inflammatory / Specialty · Hidradenitis suppurativa
Botulinum toxin a evidence for Hidradenitis suppurativa
This is an early evidence stage based mainly on observational studies and case reports. Use it as supplementary reference, and follow your doctor's judgment for treatment decisions.
Grade combines the quantity and quality of the research, while direction is a separate signal showing how the papers assess effectiveness.
Includes meta-analysis/SR Median year 2020 Last 5 years 44% Positive results 33% Negative results 1
Known in Korea as
Procedure and brand names vary, but the evidence above applies to the same procedure mechanism.
Key papers
tier1 Efficacy of non-surgical monotherapies for hidradenitis suppurativa: a systematic review and network meta-analyses of randomized trials.
Abstract summary (English) OBJECTIVE: We determined the relative efficacy of non-surgical monotherapies for hidradenitis suppurativa (HS). METHODS: Network meta-analyses were conducted to determine treatments' surface under the cumulative ranking curve (SUCRA) value (i.e. an estimate that ranks efficacy); pairwise comparisons were conducted.
Journal Article, Systematic Review, Network Meta-Analysis
View on PubMedtier1 Hyperhidrosis treatments in hidradenitis suppurativa: A systematic review.
Abstract summary (English) Hyperhidrosis impairs quality of life (QOL) in hidradenitis suppurativa (HS) patients and may exacerbate HS. However, there is limited literature on whether hyperhidrosis treatments improve HS disease. To systematically review literature on efficacy and tolerability of hyperhidrosis treatments in HS patients.
Journal Article, Systematic Review
View on PubMedtier1 Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study.
Abstract summary (English) BACKGROUND: Botulinum toxin (BTX) is a potent neurotoxin with a long history of therapeutic application in neurological and dermatological conditions, with a strong efficacy and safety profile. OBJECTIVE: Our aim was to assess whether intradermal injection with BTX-B is an effective treatment for hidradenitis suppurativa (HS). METHODS: Twenty patients with HS stage I-III disease, according to Hurley's...
Journal Article, Randomized Controlled Trial
View on PubMedtier0_review Procedural Interventions for Hidradenitis Suppurativa.
Abstract summary (English) A variety of procedures may be employed for hidradenitis suppurativa, a chronic cutaneous condition that causes abscesses, nodules, and tunnels in skinfold areas. Intralesional steroid or incision and drainage are preferred for acutely inflamed discrete lesions, while deroofing or excision may be pursued for persistent or recurrent areas. Excision and deroofing may target individual lesions or complete regions that...
Journal Article, Review
View on PubMedtier0_review Botulinum toxin type A for the management of hidradenitis suppurativa.
Abstract summary (English) Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease that centers around the hair follicle and occurs as a result of follicular occlusion. HS primarily presents as painful, inflamed lesions that begin during puberty and occur most commonly in areas with numerous apocrine glands. The etiology and pathogenesis of HS involve internal and external factors, including genetic susceptibility,...
Journal Article, Review
View on PubMedtier0_review Alternative Clinical Indications of Botulinum Toxin.
Abstract summary (English) Botulinum toxin type A (BoNTA) is a powerful neurotoxin that inhibits acetylcholine release from presynaptic vesicles. The potency and safety profile of BoNTA grant the toxin vast therapeutic potential. It has been used off-label for a variety of dermatologic conditions.
Journal Article, Review
View on PubMedtier0_review Non-cosmetic dermatological uses of botulinum neurotoxin.
Abstract summary (English) Botulinum neurotoxin (BoNT) is renowned for its inhibitory effects on the neuromuscular junction. The evidence for its use in cosmetic dermatology and in non-dermatological indications is well established. We have systemically analysed the evidence for the non-cosmetic dermatological uses of BoNT.
Journal Article, Review
View on PubMedtier3 Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage.
Abstract summary (English) Hidradenitis suppurativa is a chronic skin disease with an intense inflammatory activation. It typically affects the intertriginous areas with cysts, fistulae, and scarring extremely painful. Patients suffer from severe psychological impact.
Case Reports, Journal Article
View on PubMedtier3 Successful treatment of stage III hidradenitis suppurativa with botulinum toxin A.
Abstract summary (English) A 41-year-old obese Native American woman presented with hidradenitis suppurativa (HS) after failing all available treatment options. Her HS was more pronounced in the axillary and groin regions (Hurley stage III) and was a major source of her pain and a barrier for home exercise and aquatic therapy. She received a botulinum toxin A injection every 3 months (four times thus far), which has significantly helped...
Case Reports, Journal Article
View on PubMedPersonalized evidence report
Tell us more about your concern
and the Glass Lab bot will build a personalized report for you.
Based on the Botulinum toxin a · Hidradenitis suppurativa information on this page, we'll email you an evidence summary tailored to your skin condition and treatment stage.